Tovorafenib is a highly selective, brain-penetrating pan-RAF kinase inhibitor designed to target key enzymes in the MAPK signaling pathway. Tovorafenib has been granted Breakthrough Therapy Designation by the U.S. FDA for the treatment of pediatric patients with low-grade gliomas harboring RAF mutations. The hope is to bring this therapy soon to children in need of new treatment options.